Online ISSN: 2515-8260

Keywords : Central macular thickness


Effect of anti-diabetic drugs on central macular thickness in patients with type 2 diabetes mellitus

Dr. Sneha Pal, Dr. Priyanka Malik

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 6, Pages 643-647

Aim: To compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and healthy subjects.
Material & Methods: This is a prospective study, carried out on 92 patients. The patients were divided in to two groups: study group included 50 patients and control group comprised of 42 patients.
Results: The mean HbA1c level was 8.68 ± 2.39% in the study group and 5.10 ± 0.76% in the control group. The mean level of HbA1c was statistically higher in the study group than in the control group (Table 1, P = 0.001). Fasting plasma glucose level was statistically higher in the study group than in the control group (P= 0.001).
Conclusion: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects

Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 3160-3164

Background: Diabetic macular edema (DME) has been reported at rates of 10% and occurs more frequently in type 2 diabetes mellitus. The present study was conducted to assess the efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Materials & Methods: 60 patients with type 2 diabetes having treatment naïve, center‑involving DME of both genders were divided into 2 groups.  Group I had DME only in one eye and group II had DME in both eyes. Group I were given oral fenofibrate 160 mg/day for 6 months as a single evening dose. Central macular thickness in both groups was compared.
Results: The mean FBS was 137.6 mg/dl in group I and 158.2 mg/dl in group II, PPBS was 210.4 mg/dl and 238.6 mg/dl, blood urea (mg/dl) was 29.3 in group I and 31.5 in group II and serum creatinine (mg/dl) was 0.92 and 0.99 in group I and in group II respectively. CMT in group I and group II at baseline was 432.6 and 402.1, at 2 months was 360.2 and 358.1, at 4 months was 327.5 and 331.4 and at 6 months was 294.3 and 317.6 in group I and in group II respectively. The difference was non- significant (P>0.05).
Conclusion: Fenofibrate facilitate reduction of central macular thickness in patients with diabetic macular edema